KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Gross Profit: 2012-2024

Historic Gross Profit for Travere Therapeutics (TVTX) over the last 13 years, with Dec 2024 value amounting to $225.4 million.

  • Travere Therapeutics' Gross Profit rose 166.47% to $163.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $425.5 million, marking a year-over-year increase of 119.67%. This contributed to the annual value of $225.4 million for FY2024, which is 68.50% up from last year.
  • According to the latest figures from FY2024, Travere Therapeutics' Gross Profit is $225.4 million, which was up 68.50% from $133.8 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Gross Profit ranged from a high of $225.4 million in FY2024 and a low of $8.2 million during FY2021.
  • In the last 3 years, Travere Therapeutics' Gross Profit had a median value of $133.8 million in 2023 and averaged $154.8 million.
  • Its Gross Profit has fluctuated over the past 5 years, first crashed by 95.74% in 2021, then skyrocketed by 1,183.79% in 2022.
  • Travere Therapeutics' Gross Profit (Yearly) stood at $192.2 million in 2020, then tumbled by 95.74% to $8.2 million in 2021, then soared by 1,183.79% to $105.0 million in 2022, then increased by 27.37% to $133.8 million in 2023, then skyrocketed by 68.50% to $225.4 million in 2024.